Surf Wiki
Save to docs
general/drugs-developed-by-astrazeneca

From Surf Wiki (app.surf) — the open knowledge base

Motavizumab

Monoclonal antibody

Summary

Monoclonal antibody

| elimination_half-life =

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. , it was undergoing Phase II and III clinical trials.

In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody palivizumab.

In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development program for motavizumab. The company stated that it would no longer develop motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop motavizumab for other treatments of RSV.

References

References

  1. (December 2020). "Pharmacological management of human respiratory syncytial virus infection". Expert Opinion on Pharmacotherapy.
  2. [http://www.clinicaltrials.gov/ct2/results?term=motavizumab ClinicalTrials.gov]
  3. (3 June 2010). "FDA Panel Nixes Licensing Request for Motavizumab". Medscape.
  4. (21 December 2010). "AstraZeneca halts work on Motavizumab drug". BBC News.
Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

drugs-developed-by-astrazeneca experimental-monoclonal-antibodies
Want to explore this topic further?

Ask Mako anything about Motavizumab — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report